Based on the Johnson & Johnson stock forecast from 14 analysts, the average analyst target price for Johnson & Johnson is USD 165.13 over the next 12 months. Johnson & Johnson’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Johnson & Johnson is Neutral, which is based on 5 positive signals and 6 negative signals. At the last closing, Johnson & Johnson’s stock price was USD 156.66. Johnson & Johnson’s stock price has changed by +1.95% over the past week, +1.63% over the past month and +7.74% over the last year.
No recent analyst target price found for Johnson & Johnson
No recent average analyst rating found for Johnson & Johnson
Company Overview Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey. Read Less
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products f...Read More
Frequently Asked Questions About Johnson & Johnson (JNJ) Stock
Based on ratings from 14 analysts Johnson & Johnson's stock is Buy . Stock Target Advisor's fundamental analysis is Neutral. The stock has 15 buy, sell and 17 hold ratings.
JNJ stock's dividend yield is 3.48%.
Our analysis grades JNJ stock's dividend yield at F. This means that JNJ stock's dividend yield is above 57% of the stocks in the Drug Manufacturers - General sector in the NYE exchange.
Based on this JNJ may be a average dividend stock for its sector.
Based on targets from 14 analysts, the average taret price for JNJ is USD 165.13 over the next 12 months. The maximum analyst target price is USD 185 while the minimum anlayst target price is USD 64.
JNJ stock's Price/Earning ratio is 16.65.
Our analysis grades JNJ stock's Price / Earning ratio at C-. This means that JNJ stock's Price/Earning ratio is above 29% of the stocks in the Drug Manufacturers - General sector in the NYE exchange.
Based on this JNJ may be undervalued for its sector.
The last closing price of JNJ's stock was USD 156.66.
The most recent market capitalization for JNJ is USD 364.11B.
Based on targets from 14 analysts, the average taret price for JNJ is projected at USD 165.13 over the next 12 months.
This means that JNJ's stock price may go up by +5.40% over the next 12 months.
We can't find any ETFs which contains Johnson & Johnson's stock.
As per our most recent records Johnson & Johnson has 138,100 Employees.
Johnson & Johnson's registered address is One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933.
You can get more information about it from Johnson & Johnson's website at https://www.jnj.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Frequently Asked Questions About Johnson & Johnson (JNJ) Stock
Based on ratings from 14 analysts Johnson & Johnson's stock is Buy . Stock Target Advisor's fundamental analysis is Neutral. The stock has 15 buy, sell and 17 hold ratings.
JNJ stock's dividend yield is 3.48%.
Our analysis grades JNJ stock's dividend yield at F. This means that JNJ stock's dividend yield is above 57% of the stocks in the Drug Manufacturers - General sector in the NYE exchange.
Based on this JNJ may be a average dividend stock for its sector.
Based on targets from 14 analysts, the average taret price for JNJ is USD 165.13 over the next 12 months. The maximum analyst target price is USD 185 while the minimum anlayst target price is USD 64.
JNJ stock's Price/Earning ratio is 16.65.
Our analysis grades JNJ stock's Price / Earning ratio at C-. This means that JNJ stock's Price/Earning ratio is above 29% of the stocks in the Drug Manufacturers - General sector in the NYE exchange.
Based on this JNJ may be undervalued for its sector.
The last closing price of JNJ's stock was USD 156.66.
The most recent market capitalization for JNJ is USD 364.11B.
Based on targets from 14 analysts, the average taret price for JNJ is projected at USD 165.13 over the next 12 months.
This means that JNJ's stock price may go up by +5.40% over the next 12 months.
We can't find any ETFs which contains Johnson & Johnson's stock.
As per our most recent records Johnson & Johnson has 138,100 Employees.
Johnson & Johnson's registered address is One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933.
You can get more information about it from Johnson & Johnson's website at https://www.jnj.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for JNJ !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
